RC
CYTK icon

RegentAtlantic Capital’s Cytokinetics CYTK Stock Holding History

RegentAtlantic Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-750
Closed -$6.01K – 485
2014
Q4 		$6.01K Buy
+750
New +$3.22K ﹤0.01% 987

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RegentAtlantic Capital's CYTK Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Cytokinetics (CYTK) in Q1 2015, closing a stake of 750 shares — an estimated $6.01K sold.

RegentAtlantic Capital first reported a position in CYTK in Q4 2014 and held it in 1 quarter. The position peaked at $6.01K in Q4 2014. 94 funds tracked by Wall St. Rank hold CYTK as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Cytokinetics position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 750 Cytokinetics shares in Q1 2015, an estimated $6.01K.
  • RegentAtlantic Capital first reported a position in Cytokinetics in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Cytokinetics position peaked at $6.01K in Q4 2014.
  • 94 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.